AbbVie Dual Anti Cancer New Drug Declares for Market in China
王俊杰2017
发表于 8 小时前
113
0
0
On November 6th, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration stated that AbbVie's application for the launch of a new drug, a concentrated solution for injection of cetuximab, has been accepted. This innovative therapy was previously listed by industry media Evalute as one of the top ten potential heavyweight therapies for 2023.
According to publicly available information from AbbVie, EPCRITAMAB (trade name: Epkinly) is a CD3/CD20 bispecific antibody that has been approved by the US FDA for the treatment of diffuse large B-cell lymphoma and follicular lymphoma. EPCoritamab is jointly developed by AbbVie and Genmab, and the two companies will share commercialization responsibilities in the United States and Japan. AbbVie will be responsible for further global commercialization of the product.
In May 2023, EPCRITAMAB received its first accelerated approval from the US FDA for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In June of this year, EPCRITAMAB was once again approved by the FDA for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who had previously received systemic therapy beyond line 2.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- General Motors Q3 sold over 420000 vehicles in China, surpassing gasoline powered vehicles for the first time in new energy vehicles
- Has the 'fixed price' policy been effective? General Motors' sales in China increased by 14.3% month on month in the third quarter, and SAIC GM's orders for certain models were overstocked
- Hyatt Hotels and China Resources Land establish a joint venture for light asset expansion, continuing to expand into the Chinese market
- The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
- When will Apple AI be launched in China? Cook responds!
- Dialogue with Meng Pu, Chairman of Qualcomm China: Qualcomm has long-term accumulation in China and will adhere to the path of self-developed chips
- This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
-
随着“银十”结束,各家造车新势力都交出了一份亮眼的成绩单。 理想领跑10月新势力交付榜,鸿蒙智行重回4万辆,零跑、深蓝、极氪、小鹏等单月交付量均创新高,岚图、阿维塔、智己等实现破万,但哪吒却消失在 ...
- fanadam
- 昨天 20:02
- 支持
- 反对
- 回复
- 收藏
-
【科技记者古尔曼:苹果计划于12月第一周发布iOS 18.2系统更新 带来更多人工智能功能】科技记者古尔曼透露,苹果计划于12月第一周发布iOS 18.2系统更新。iOS 18.2将为iPhone 15 Pro机型和所有iPhone 16机型带来更多 ...
- cristianna
- 前天 17:32
- 支持
- 反对
- 回复
- 收藏
-
为期超七周的大罢工终于落下帷幕。 当地时间11月4日,波音美国西海岸工厂工人们就改进后的合同提案投票。 随后,代表着波音超过33000名西雅图地区机械师的IAM工会经表决,以59%的同意票决定接纳波音提 ...
- cristianna
- 昨天 16:55
- 支持
- 反对
- 回复
- 收藏
-
近日,爱立信中国区总裁方迎在接受《经济参考报》记者采访时表示,5G技术在全球范围内得到了迅速发展,但面临商业潜力未能充分挖掘、网络运营难度较以往更高两大挑战。因此,运营商在继续5G网络部署的同时,应关 ...
- blueskybb
- 前天 15:05
- 支持
- 反对
- 回复
- 收藏